重大事件
即時報告
8-K
2026-06-11
Atossa Therapeutics 披露簽訂重大最終協議 市場關注乳癌藥物合作或融資
AI 繁中摘要
Atossa Therapeutics（NASDAQ: ATOS）於2026年6月11日向SEC提交8-K（當前報告），報告日期為2026年6月10日。該公司披露已簽訂一項重大最終協議（Item 1.01），並同時提供相關財務報表及附件（Item 9.01）。附帶文件包括EX-4.1（協議）、EX-5.1（法律意見）、EX-10.1（重大協議全文）及EX-23.1（同意書）。協議具體條款尚未公開，但根據公司專注於乳癌治療藥物的業務性質，市場猜測該協議可能涉及授權、合作或融資安排。投資者應密切留意協議細節，因任何戰略性合作或資金注入均可能影響公司研發進度及股價表現。目前未有管理層展望或具體財務數字披露。
展開英文正文
EDGAR Filing Documents for 0001193125-26-266717 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-266717 Filing Date 2026-06-11 Accepted 2026-06-11 08:00:15 Documents 16 Period of Report 2026-06-10 Items Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K atos-20260610.htm iXBRL 8-K 69947 2 EX-4.1 atos-ex4_1.htm EX-4.1 153518 3 EX-5.1 atos-ex5_1.htm EX-5.1 21842 4 EX-10.1 atos-ex10_1.htm EX-10.1 328363 5 EX-23.1 atos-ex23_1.htm EX-23.1 1108 6 GRAPHIC img187741201_0.gif GRAPHIC 3601 7 GRAPHIC img187741201_1.gif GRAPHIC 3601 8 GRAPHIC gfx187741201_0.jpg GRAPHIC 1187 Complete submission text file 0001193125-26-266717.txt 783095 Data Files Seq Description Document Type Size 9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20260610.xsd EX-101.SCH 26890 19 EXTRACTED XBRL INSTANCE DOCUMENT atos-20260610_htm.xml XML 4702 Mailing Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107 Business Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107 206.588.0256 ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings) EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 261081469 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)